• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >IL-2 therapy in type 1 diabetes: 'Trials' and tribulations
【24h】

IL-2 therapy in type 1 diabetes: 'Trials' and tribulations

机译：1型糖尿病的IL-2治疗：“试验”和磨难

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IL-2 facilitates immunity or tolerance depending on its availability. In model systems, it is well established that low dose IL-2 promotes selective expansion of regulatory T cells (Treg), an IL-2 responsive cell type known to control autoimmunity. Moreover, many autoimmune diseases are marked by defects in Treg and/or IL-2/IL-2 receptor signaling. Thus, patients with immune-mediated diseases were treated with IL-2 with the goal of increasing Treg and controlling autoimmunity. In graft versus host disease, HCV-induced vasculitis and type 1 diabetes (T1D), Treg numbers increased with IL-2 therapy. Yet there was no relationship between Treg number and clinical outcome. In fact, in T1D subjects treated with rapamycin and IL-2 therapy there was no measureable clinical benefit. In this review, we compare results from IL-2 treatment of patients with immune-mediated diseases, discuss possible mechanisms of IL-2 treatment and suggest future directions for use of IL-2 therapy in T1D.
机译：IL-2有助于免疫或耐受，具体取决于其可用性。在模型系统中，众所周知，低剂量的IL-2会促进调节性T细胞（Treg）的选择性扩增，而调节性T细胞是已知可控制自身免疫的IL-2应答细胞类型。此外，许多自身免疫性疾病的特征在于Treg和/或IL-2 / IL-2受体信号传导的缺陷。因此，以增加Treg和控制自身免疫为目标，用IL-2治疗免疫介导疾病的患者。在移植物抗宿主病，HCV诱发的血管炎和1型糖尿病（T1D）中，IL-2治疗可增加Treg数量。然而，Treg数量与临床结果之间没有关系。实际上，在接受雷帕霉素和IL-2治疗的T1D受试者中，没有可测量的临床益处。在这篇综述中，我们比较了IL-2治疗免疫介导疾病患者的结果，讨论了IL-2治疗的可能机制，并提出了在T1D中使用IL-2治疗的未来方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号